Nano delivers big: Designing molecular missiles for cancer therapeutics

Pharmaceutics

Volumn 3, Issue 1, 2011, Pages 34-52

  Patel, Sachin ^a   Bhirde, Ashwin A ^b   Rusling, James F ^c,d   Chen, Xiaoyuan ^b   Gutkind, Silvio ^a   Patel, Vyomesh ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Cancer; Carbon nanotube; Drug delivery; Gene delivery; Nano material; Nano toxicity; SiRNA

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON NANOTUBE; CISPLATIN; DENDRIMER; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR; LIPOPROTEIN; LIPOSOME; METAL; METAL OXIDE; NANOCARRIER; NANOPARTICLE; NANOSPHERE; PACLITAXEL; POLYMER; SMALL INTERFERING RNA;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SPECIFICITY; DRUG TARGETING; GENE DELIVERY SYSTEM; HAND FOOT SYNDROME; HUMAN; KAPOSI SARCOMA; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; REVIEW;

EID: 79953714588     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics3010034     Document Type: Review

References (109)

1. Caruthers, S.D.; Wickline, S.A.; Lanza, G.M. Nanotechnological applications in medicine. Curr. Opin. Biotechnol. 2007, 18, 26-30.
2. Grobmyer, S.R.; Iwakuma, N.; Sharma, P.; Moudgil, B.M. What is cancer nanotechnology? Methods Mol. Biol. 2010, 624, 1-9.
3. Emerich, D.F.; Thanos, CG. Nanotechnology and medicine. Expert Opin. Biol. Ther. 2003, 3, 655-663.
4. Rao, C.N.R.; Muller, A.; Cheetham, A.K. The Chemistry of Nanomaterials: Synthesis, Properties and Applications; John Wiley & Sons: Oxford, England, 2004; p. 761.
5. Farokhzad, O.C.; Langer, R. Nanomedicine: Developing smarter therapeutic and diagnostic modalities. Adv. Drug Delivery Rev. 2006, 58, 1456-1459.
6. Roco, M.C. Nanotechnology: Convergence with modern biology and medicine. Curr. Opin. Biotechnol. 2003,14, 337-346.
7. Ferrari, M. Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer 2005, 5, 161-171.
8. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Nanomedicine: Current status and future prospects. FASEBJ. 2005, 19, 311-330.
9. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59, 225-249.
10. Petros, R.A.; DeSimone, J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010, 9, 615-627.
11. Gaitanis, A.; Staal, S. Liposomal doxorubicin and nab-paclitaxel: Nanoparticle cancer chemotherapy in current clinical use. Methods Mol. Biol. 2010, 624, 385-392.
12. Fanciullino, R.; Ciccolini, J. Liposome-encapsulated anticancer drugs: Still waiting for the magic bullet? Curr. Med. Chem. 2009, 16, 4361-4371.
13. Ali, I. Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives. Curr. Cancer Drug Targets 2010, In Press.
14. Utreja, P.; Jain, S.; Tiwary, A.K. Novel drug delivery systems for sustained and targeted delivery of anti- cancer drugs: Current status and future prospects. Curr. DrugDeliv. 2010, 7, 152-161.
15. Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434, 913-917.
16. Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, L; Knights, C; Martin, N.M.; Jackson, S.P.; Smith, G.C.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434, 917-921.
17. Helleday, T.; Bryant, H.E.; Schultz, N. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 2005, 4, 1176-1178.
18. Torchilin, V.P. Passive and active drug targeting: Drug delivery to tumors as an example. Handb. Exp. Pharmacol. 2010, 197, 3-53.
19. Xie, J.; Lee, S.; Chen, X. Nanoparticle-based theranostic agents. Adv. Drug Delivery Rev. 2010, 62, 1064-1079.
20. Wang, H.; Chen, X. Applications for site-directed molecular imaging agents coupled with drug delivery potential. Expert Opin. DrugDeliv. 2009, 6, 745-768.
21. Alexis, F.; Pridgen, E.M.; Langer, R.; Farokhzad, O.C. Nanoparticle technologies for cancer therapy. Handb. Exp. Pharmacol. 2010, 197, 55-86.
22. Kaasgaard, T.; Andresen, T.L. Liposomal cancer therapy: Exploiting tumor characteristics. Expert Opin. DrugDeliv. 2010, 7, 225-243.
23. Plosker, G.L. Pegylated liposomal Doxorubicin: A review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 2008, 68, 2535-2551.
24. Astruc, D.; Boisselier, E.; Ornelas, C. Dendrimers designed for functions: From physical, photophysical, and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics, and nanomedicine. Chem. Rev. 2010, 110, 1857-1959.
25. Calderon, M.; Quadir, M.A.; Sharma, S.K.; Haag, R. Dendritic polyglycerols for biomédical applications. Adv. Mater. 2010, 22, 190-218.
26. Gajbhiye, V.; Palanirajan, V.K.; Tekade, R.K.; Jain, N.K. Dendrimers as therapeutic agents: A systematic review. J. Pharm. Pharmacol. 2009, 61, 989-1003.
27. De Souza, R.; Zahedi, P.; Allen, C.J.; Piquette-Miller, M. Polymeric drug delivery systems for localized cancer chemotherapy. DrugDeliv. 2010, 17, 365-375.
28. Joralemon, M.J.; McRae, S.; Emrick, T. PEGylated polymers for medicine: From conjugation to self-assembled systems. Chem. Commun. (Comb) 2010, 46, 1377-1393.
29. Luten, J.; van Nostrum, CF.; De Smedt, S.C.; Hennink, W.E. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J. Control. Release 2008, 126, 97-110.
30. Ahmad, M.Z.; Akhter, S.; Jain, G.K.; Rahman, M.; Pathan, S.A.; Ahmad, F.J.; Khar, R.K. Metallic nanoparticles: Technology overview & drug delivery applications in oncology. Expert Opin. DrugDeliv. 2010, 7, 927-942.
31. Prato, M.; Kostarelos, K.; Bianco, A. Functionalized carbon nanotubes in drug design and discovery. Ace. Chem. Res. 2008, 41, 60-68.
32. Kostarelos, K.; Bianco, A.; Prato, M. Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. Nat. Nanotechnol. 2009, 4, 627-633.
33. Moser, G.; Vacariu-Granser, G.V.; Schneider, C; Abatzi, T.A.; Pokieser, P.; Stacher-Janotta, G.; Gaupmann, G.; Weber, U.; Wenzel, T.; Roden, M.; et al. High incidence of esophageal motor disorders in consecutive patients with globus sensation. Gastroenterology 1991, 101, 1512-1521.
34. Akbar, S.; Taimoor, A.A. Functionalization of carbon nanotubes: Manufacturing techniques and properties of customized nanocomponents for molecular-level technology. Recent Patents Nanotechnol. 2009, 3, 154-161.
35. Tulenko, T.N.; Sumner, A.E. The physiology of lipoproteins. J. Nucl. Cardiol. 2002, 9, 638-649.
36. Lacko, A.G.; Nair, M.; Prokai, L.; McConathy, W.J. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Expert Opin. Drug Deliv. 2007, 4, 665-675.
37. Carrero-Sanchez, J.C.; Elias, A.L.; Mancilla, R.; Arrellin, G.; Terrones, H.; Laclette, J.P.; Terrones, M. Biocompatibility and toxicological studies of carbon nanotubes doped with nitrogen. NanoLett. 2006, 6, 1609-1616.
38. Bhirde, A.A.; Patel, S.; Sousa, A.A.; Patel, V.; Molinolo, A.A.; Ji, Y.; Leapman, R.D.; Gutkind, J.S.; Rusling, J.F. Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice. Nanomedicine (Lond) 2010, 5, 1535-1546.
39. Edri, E.; Regev, O. Shaken, not stable: Dispersion mechanism and dynamics of protein-dispersed nanotubes studied via spectroscopy. Langmuir 2009, 25, 10459-10465.
40. Karousis, N.; Tagmatarchis, N.; Tasis, D. Current progress on the chemical modification of carbon nanotubes. Chem. Rev. 2010, 110, 5366-5397.
41. Scheinberg, D.A.; Villa, C.H.; Escorcia, F.E.; McDevitt, M.R. Conscripts of the infinite armada: Systemic cancer therapy using nanomaterials. Nat. Rev. Clin. Oncol. 2010, 7, 266-276.
42. Kim, J.; Piao, Y.; Hyeon, T. Multifunctional nanostructured materials for multimodal imaging, and simultaneous imaging and therapy. Chem. Soc. Rev. 2009, 38, 372-390.
43. Subbiah, R.; Veerapandian, M.; Yun, K.S. Nanoparticles: Functionalization and Multifunctional Applications in Biomédical Sciences. Curr. Med. Chem. 2010, 17, 4559-4577.
44. Hart, S.L. Multifunctional nano complexes for gene transfer and gene therapy. Cell Biol. Toxicol. 2010,26,69-81.
45. Dharmapuri, S.; Peruzzi, D.; Aurisicchio, L. Engineered adenovirus serotypes for overcoming anti-vector immunity. Expert Opin. Biol. Ther. 2009, 9, 1279-1287.
46. Goyal, A.K.; Khatri, K.; Vyas, S.P. Patents on non-viral mediated gene delivery. Recent Patents DNA Gene Seq. 2008, 2, 44-60.
47. Khurana, B.; Goyal, A.K.; Budhiraja, A.; Arora, D.; Vyas, S.P. siRNA delivery using nanocarriers - an efficient tool for gene silencing. Curr. Gene Ther. 2010, 10, 139-155.
48. Thomas, CE.; Ehrhardt, A.; Kay, M.A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 2003, 4, 346-358.
49. Heidel, J.D.; Yu, Z.; Liu, J.Y.; Rele, S.M.; Liang, Y.; Zeidan, R.K.; Kornbrust, DJ.; Davis, M.E. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sei. USA 2007, 104, 5715-5721.
50. Takeshita, F.; Minakuchi, Y.; Nagahara, S.; Honma, K.; Sasaki, H.; Hirai, K.; Teratani, T.; Namatame, N; Yamamoto, Y.; Hanai, K.; Kato, T.; Sano, A.; Ochiya, T. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sei. USA 2005, 102, 12177-12182.
51. Ferrari, M. Frontiers in cancer nanomedicine: Directing mass transport through biological barriers. Trends Biotechnol. 2010, 28, 181-188.
52. Tanaka, T.; Mangala, L.S.; Vivas-Mejia, P.E.; Nieves-Alicea, R.; Mann, A.P.; Mora, E.; Han, H.D.; Shahzad, M.M.; Liu, X.; Bhavane, R.; Gu, J.; Fakhoury, J.R.; Chiappini, C; Lu, C; Matsuo, K.; Godin, B.; Stone, R.L.; Nick, A.M.; Lopez-Berestein, G.; Sood, A.K.; Ferrari, M. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010, 70, 3687-3696.
53. Chakravarty, P.; Qian, W.; El-Sayed, M.A.; Prausnitz, M.R. Delivery of molecules into cells using carbon nanoparticles activated by femtosecond laser pulses. Nat. Nanotechnol. 2010, 5, 607-611.
54. Gao, X.; Zhang, P. Transgenic RNA interference in mice. Physiology (Bethesda) 2007, 22, 161-166.
55. Takahashi, Y.; Nishikawa, M.; Takakura, Y. Nonviral vector-mediated RNA interference: Its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. Adv. Drug Delivery Rev. 2009, 61, 760-766.
56. Tao, W.; Davide, J.P.; Cai, M.; Zhang, G.J.; South, V.J.; Matter, A.; Ng, B.; Zhang, Y.; Sepp-Lorenzino, L. Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver. Mol. Ther. 2010, 18, 1657-1666.
57. Davis, M.E.; Zuckerman, J.E.; Choi, C.H.; Seligson, D.; Tolcher, A.; Alabi, CA.; Yen, Y.; Heidel, J.D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464, 1067-1070.
58. Davis, M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol. Pharm. 2009, 6, 659-668.
59. Singh, R.; Pantarotto, D.; McCarthy, D.; Chaloin, O.; Hoebeke, J.; Partidos, CD.; Briand, J.P.; Prato, M.; Bianco, A.; Kostarelos, K. Binding and condensation of plasmid DNA onto functionalized carbon nanotubes: Toward the construction of nanotube-based gene delivery vectors. J. Am. Chem. Soc. 2005, 127, 4388-4396.
60. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57-70.
61. Bhirde, A.A.; Patel, V.; Gavard, J.; Zhang, G.; Sousa, A.A.; Masedunskas, A.; Leapman, R.D.; Weigert, R.; Gutkind, J.S.; Rusling, J.F. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACSNano 2009, 3, 307-316.
62. Bhirde, A.A.; Sousa, A.A.; Patel, V.; Azari, A.A.; Gutkind, J.S.; Leapman, R.D.; Rusling, J.F. Imaging the distribution of individual platinum-based anticancer drug molecules attached to single-wall carbon nanotubes. Nanomedicine (Lond) 2009, 4, 763-772.
63. Tarahovsky, Y.S. Smart liposomal nanocontainers in biology and medicine. Biochemistry (Mose) 2010, 75,811-824.
64. Quan, C.Y.; Chen, J.X.; Wang, H.Y.; Li, C; Chang, C; Zhang, X.Z.; Zhuo, R.X. Core-shell nanosized assemblies mediated by the alpha-beta cyclodextrin dimer with a tumor-triggered targeting property. ACSNano 2010, 4, 4211-4219.
65. Medina, O.P.; Zhu, Y.; Kairemo, K. Targeted liposomal drug delivery in cancer. Curr. Pharm. Des. 2004,70,2981-2989.
66. Koivunen, E.; Arap, W.; Valtanen, H.; Rainisalo, A.; Medina, O.P.; Heikkila, P.; Kantor, C; Gahmberg, CG.; Salo, T.; Konttinen, Y.T.; Sorsa, T.; Ruoslahti, E.; Pasqualini, R. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 1999, 77, 768-774.
67. O'Neal, D.P.; Hirsch, L.R.; Halas, N.J.; Payne, J.D.; West, J.L. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett. 2004,209, 171-176.
68. El-Sayed, I.H.; Huang, X.; El-Sayed, M.A. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 2006, 239, 129-135.
69. Kim, K.; Kim, J.H.; Park, H.; Kim, Y.S.; Park, K.; Nam, H.; Lee, S.; Park, J.H.; Park, R.W.; Kim, I.S.; Choi, K.; Kim, S.Y.; Kwon, I.C. Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J. Control. Release 2010, 146, 219-227.
70. Quintana, M.; Prato, M. Supramolecular aggregation of functionalized carbon nanotubes. Chem. Commun. (Camb) 2009, 40, 6005-6007.
71. Kostarelos, K. The long and short of carbon nanotube toxicity. Nat. Biotechnol. 2008, 26, 114-116.
72. De Jong, W.H.; Borm, P.J. Drug delivery and nanoparticles: Applications and hazards. Int. J. Nanomedicine 2008, 3, 133-149.
73. Bhirde, A.; Xie, J.; Swierczewska, M.; Chen, X. Nanoparticles for cell labeling. Nanoscale 2010, doi: 10.1039/C0NR00493F.
74. Poland, CA.; Duffin, R.; Kinloch, I.; Maynard, A.; Wallace, W.A.; Seaton, A.; Stone, V.; Brown, S.; Macnee, W.; Donaldson, K. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat. Nanotechnol. 2008, 3, 423-428.
75. Cherukuri, P.; Bachilo, S.M.; Litovsky, S.H.; Weisman, R.B. Near-infrared fluorescence microscopy of single-walled carbon nanotubes in phagocytic cells. J. Am. Chem. Soc. 2004, 126, 15638-15639.
76. Sayes, CM.; Liang, F.; Hudson, J.L.; Mendez, J.; Guo, W.; Beach, J.M.; Moore, V.C; Doyle, CD.; West, J.L.; Billups, W.E.; Ausman, K.D.; Colvin, V.L. Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro. Toxicol. Lett. 2006, 161, 135-142.
77. Dumortier, H.; Lacotte, S.; Pastorin, G.; Marega, R.; Wu, W.; Bonifazi, D.; Briand, J.P.; Prato, M.; Müller, S.; Bianco, A. Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. Nano Lett. 2006, 6, 1522-1528.
78. Cui, H.F.; Vashist, S.K.; Al-Rubeaan, K.; Luong, J.H.; Sheu, F.S. Interfacing carbon nanotubes with living mammalian cells and cytotoxicity issues. Chem. Res. Toxicol. 2010, 23, 1131-1147.
79. Veronese, F.M.; Pasut, G. PEGylation, successful approach to drug delivery. Drug Discov. Today 2005,70, 1451-1458.
80. Liu, Z.; Sun, X.; Nakayama-Ratchford, N.; Dai, H. Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. ACS Nano 2007, 1, 50-56.
81. Owens, D.E.; Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307, 93-102.
82. Ryan, S.M.; Mantovani, G.; Wang, X.; Haddleton, D.M.; Brayden, DJ. Advances in PEGylation of important biotech molecules: Delivery aspects. Expert Opin. Drug Deliv. 2008, 5, 371-383.
83. Wang, A.Z.; Gu, F.; Zhang, L.; Chan, J.M.; Radovic-Moreno, A.; Shaikh, M.R.; Farokhzad, O.C. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin. Biol. Ther. 2008, 8, 1063-1070.
84. Fifis, T.; Gamvrellis, A.; Crimeen-Irwin, B.; Pietersz, G.A.; Li, J.; Mottram, P.L.; McKenzie, IF.; Plebanski, M. Size-dependent immunogenicity: Therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 2004, 173, 3148-3154.
85. Linkov, I; Satterstrom, F.K.; Corey, L.M. Nanotoxicology and nanomedicine: Making hard decisions. Nanomedicine 2008, 4, 167-171.
86. Canis, L.; Linkov, I.; Seager, T.P. Application of stochastic multiattribute analysis to assessment of single walled carbon nanotube synthesis processes. Environ. Sei. Technol. 2010, 44, 8704-8711.
87. Nagar, S. Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy. Adv. Exp. Med. Biol. 2010, 678, 124-132.
88. Batist, G. Cardiac safety of liposomal anthracyclines. Cardiovasc. Toxicol. 2007, 7,72-74
89. von Moos, R.; Thuerlimann, B.J.; Aapro, M.; Rayson, D.; Harrold, K.; Sehouli, J.; Scotte, F.; Lorusso, D.; Dummer, R.; Lacouture, M.E.; Lademann, J.; Hauschild, A. Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts. Eur. J. Cancer 2008, 44, 781-790.
90. Iglesias, J. Nab-Paclitaxel (Abraxane(R)): An albumin-bound cytotoxic exploiting natural delivery mechanisms into tumors. Breast Cancer Res. 2009, 11 (Suppl. 1), S21.
91. National Cancer Institute. Nanotechnology in Clinical Trials. Access on http://nano.cancer.gov/learn/now/clinical-trials.asp.
92. Shimada, H.; Matsubara, H.; Shiratori, T.; Shimizu, T.; Miyazaki, S.; Okazumi, S.; Nabeya, Y.; Shuto, K.; Hayashi, H.; Tanizawa, T.; Nakatani, Y.; Nakasa, H.; Kitada, M.; Ochiai, T. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sei. 2006, 97, 554-561.
93. Sharma, A.; Tandon, M.; Bangari, D.S.; Mittal, S.K. Adenoviral vector-based strategies for cancer therapy. Curr. Drug ther. 2009,4,117-138.
94. Schwartz, J.A.; Shetty, A.M.; Price, R.E.; Stafford, R.J.; Wang, J.C.; Uthamanthil, R.K.; Pham, K.; McNichols, R.J.; Coleman, C.L.; Payne, J.D. Feasibility study of particle-assisted laser ablation of brain tumors in orthotopic canine model. Cancer Res. 2009, 69, 1659-1667.
95. Radu, CG.; Shu, C.J.; Nair-Gill, E.; Shelly, S.M.; Barrio, J.R.; Satyamurthy, N.; Phelps, M.E.; Witte, O.N. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog. Nat. Med. 2008, 14, 783-788.
96. Ross, R.W.; Zietman, A.L.; Xie, W.; Coen, J.J.; Dahl, D.M.; Shipley, W.U.; Kaufman, D.S.; Islam, T.; Guimaraes, A.R.; Weissleder, R.; Harisinghani, M. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node métastases in prostate cancer patients prior to salvage radiation therapy. Clin. Imag. 2009, 33, 301-305.
97. Paraskar, A.S.; Soni, S.; Chin, K.T.; Chaudhuri, P.; Muto, K.W.; Berkowitz, J.; Handlogten, M.W.; Alves, N.J.; Bilgicer, B.; Dinulescu, D.M.; Masheikar, R.A.; Sengupta, S. Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc. Natl. Acad. Sei. USA 2010, 707, 12435-12440.
98. Liu, Z.; Fan, A.C.; Rakhra, K.; Sherlock, S.; Goodwin, A.; Chen, X.; Yang, Q.; Felsher, D.W.; Dai, H. Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem. Int. Ed. Engl. 2009, 48, 7668-7672.
99. Liu, Z.; Tabakman, S.M.; Chen, Z.; Dai, H. Preparation of carbon nanotube bioconjugates for biomédical applications. Nat. Protoc. 2009, 4, 1372-1382.
100. Prencipe, G.; Tabakman, S.M.; Welsher, K.; Liu, Z.; Goodwin, A.P.; Zhang, L.; Henry, J.; Dai, H. PEG branched polymer for functionalization of nanomaterials with ultralong blood circulation. J. Am. Chem. Soc. 2009, 131, 4783-4787.
101. Liu, Z.; Chen, K.; Davis, C; Sherlock, S.; Cao, Q.; Chen, X.; Dai, H. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 2008, 68, 6652-6660.
102. Schipper, M.L.; Nakayama-Ratchford, N.; Davis, C.R.; Kam, N.W.; Chu, P.; Liu, Z.; Sun, X.; Dai, H.; Gambhir, S.S. A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice. Nat. Nanotechnol. 2008, 3, 216-221.
103. Liu, Z.; Cai, W.; He, L.; Nakayama, N.; Chen, K.; Sun, X.; Chen, X.; Dai, H. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol. 2007, 2, 47-52.
104. Cai, W.; Chen, X. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 2008, 49 (Suppl. 2), 113S-128S.
105. Cai, W.; Chen, X. Nanoplatforms for targeted molecular imaging in living subjects. Small 2007, 3, 1840-1854.
106. Lammers, T.; Kiessling, F.; Hennink, W.E.; Storm, G. Nanotheranostics and image-guided drug delivery: Current concepts and future directions. Mol. Pharm. 2010, 7, 1899-1912.
107. Xie, J.; Chen, K.; Huang, J.; Lee, S.; Wang, J.; Gao, J.; Li, X.; Chen, X. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials 2010, 31, 3016-3022.
108. MacKay, J.A.; Li, Z. Theranostic agents that co-deliver therapeutic and imaging agents? Adv. DrugDeliv. Rev. 2010, 62, 1003-1004.
109. Xie, J.; Huang, J.; Li, X.; Sun, S.; Chen, X. Iron oxide nanoparticle platform for biomédical applications. Curr.Med. Chem. 2009, 16, 1278-1294.